All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Rutgers Cancer Institute of New Jersey and its Top Research Leader Dr. Eileen White Selected to Lead Global Cancer Grand Challenges Team Taking on Cancer Cachexia

July 13th 2022

A world-class team of researchers assembled and led by Rutgers Cancer Institute of New Jersey and its Deputy Director and Chief Scientific Officer Eileen White, PhD, has been awarded a $25 million Cancer Grand Challenges grant to tackle the condition of cancer cachexia.

Cabozantinib Demonstrates Long-Term PFS Benefit in Radioiodine-Refractory Differentiated Thyroid Cancer

July 13th 2022

Cabozantinib monotherapy maintained continued to provide a superior progression-free survival benefit to that achieved with placebo in adults with locally advanced or metastatic differentiated thyroid carcinoma, irrespective of histology, according to updated data from the phase 3 COSMIC-311 trial.

FDA Grants Orphan Drug, Fast Track Designations to CV-01 in Recurrent Glioblastoma

July 13th 2022

CV-01, Alpheus Medical’s novel sonodynamic therapy delivery platform, has received orphan drug and fast track designations from the FDA for the treatment of patients with recurrent glioblastoma.

Mayo Clinic Physicians Seek to Address Bias in Medical Education

July 13th 2022

The clinical learning environment for medical trainees is the foundation of medical training programs.

Ibrutinib/Obinutuzumab Combo Elicits Durable Responses in Relapsed/Refractory CLL

July 13th 2022

Findings from a phase 1b trial showed that the addition of obinutuzumab to ibrutinib produced a complete response rate that compared favorably with what has historically been observed with ibrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.

FDA Removes Clinical Hold on FLAMINGO-01 Trial in High-Risk HER2/Neu-Positive Breast Cancer

July 12th 2022

The FDA has removed the clinical hold on the phase 3 FLAMINGO-01 trial allowing the study to continue elevating the activity and safety of the HER2/neu-peptide GLSI-100 in patients with HER2/neu-positive breast cancer who are at high risk for disease recurrence or have residual disease following completion of neoadjuvant and adjuvant trastuzumab-based therapy, according to an announcement from the drug developer.

ADCs and TKIs Plus Immunotherapy Signal the Future of Urothelial Carcinoma and RCC

July 12th 2022

Benjamin Garmezy, MD, discussed the positive trajectory of antibody-drug conjugates and immunotherapy in urothelial carcinoma, highlighting the importance of considering individual patient eligibility for treatments like first-line chemotherapy.

FOR46 Shows Early Antitumor Activity in Metastatic Castration-Resistant Prostate Cancer

July 12th 2022

The CD46-targeted antibody-drug conjugate FOR46 demonstrated encouraging evidence of antitumor activity in patients with metastatic castration-resistant prostate cancer with a safety profile that proved to be similar to other monomethyl auristatin E–based ADCs, according to data from a phase 1a/1b trial.

FDA Accepts BLA for Trastuzumab Duocarmazine for Advanced HER2+ Breast Cancer

July 12th 2022

The FDA has accepted for review a biologics license application for vic-trastuzumab duocarmazine for the treatment of patients with HER2-positive unresectable locally advanced or metastatic breast cancer.

Stearns Elaborates on the Evolution of ADCs in HER2+ and HER2-Low Breast Cancer

July 12th 2022

Vered Stearns, MD, FASCO, discusses how DESTINY-Breast04 has shifted the treatment paradigm for patients with HER2-low breast cancer, the exploration of treatment combinations being optimized in breast cancer, and the expansion of the treatment paradigm in triple-negative breast cancer.

Florida Cancer Specialists & Research Institute Expands Access to Gynecologic Oncology in Palm Beach County

July 12th 2022

Florida Cancer Specialists & Research Institute has expanded access to specialized gynecologic oncology care with the addition of Board-certified gynecologic oncologist Christopher McCann, DO.

Fellows Can Join the Fight Against Cancer Misinformation Online

July 12th 2022

Many cancer organizations across the United States and internationally acknowledge a need for in-novative uses of social technology to improve cancer-related support and information provision.

Camidanlumab Tesirine Elicits Encouraging Responses in Relapsed/Refractory Classical Hodgkin Lymphoma

July 12th 2022

Camidanlumab tesirine induced an overall response rate of 70.1% in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma who previously received brentuximab vedotin and a PD-1 blockade with or without stem cell transplant.

FDA Grants Fast Track Designation to Abelacimab for Thrombosis Associated With Cancer

July 11th 2022

The FDA has granted a fast track designation to abelacimab for the treatment of thrombosis associated with cancer.

Survival is Significantly Poorer for Young Black Patients With AML Compared With White Counterparts

July 11th 2022

Despite receiving similar treatment, Black patients between the ages of 18 and 29 years with acute myeloid leukemia were twice as likely to die within 5 years compared with Whites.

Cabozantinib Plus Nivolumab/Ipilimumab Meets PFS End Point in Untreated Advanced RCC

July 11th 2022

The addition of cabozantinib to nivolumab and ipilimumab generated a significant improvement in progression-free survival vs nivolumab/ipilimumab alone as a first-line treatment for patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma, meeting the primary end point of the phase 3 COSMIC-313 trial.

Short Course of Oxaliplatin/Fluoropyrimidine Noninferior for DFS, Neuropathy in High-Risk CRC

July 11th 2022

A 3-month course of oxaliplatin produced disease-free survival noninferior to a 6-month course in patients with high-risk stage II and III colorectal cancer.

Individualized Care Drives Treatment Focus in AML, DLBCL, and CLL

July 11th 2022

Ehab Atallah, MD, explains how patient characteristics influence current treatment strategies in acute myeloid leukemia, how frontline pirtobrutinib may move toward use in chronic lymphocytic leukemia, and the growing evidence favoring CAR T-cell therapy as an effective treatment option in CLL.

Enoblituzumab Trial Ended Early Due to Safety Concerns in Head and Neck Squamous Cell Carcinoma

July 11th 2022

The phase 2 CP-MGA271-06 trial closed early following an internal review of safety data of enoblituzumab plus retifanlimab or tebotelimab as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.

American Oncology Network Physicians Research Presented at ASCO 2022

July 11th 2022

American Oncology Network, LLC is pleased to announce that three research studies co-authored by AON physicians were presented at the American Society of Clinical Oncology 2022 Annual Meeting, held June 3-7, 2022.